MARKET

HBPCF

HBPCF

Helix Biopharma
OTCPK
0.660
NaN%
Closed 09:30 02/12 EST
OPEN
--
PREV CLOSE
0.660
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
0.915
52 WEEK LOW
0.660
MARKET CAP
50.41M
P/E (TTM)
-11.0924
1D
5D
1M
3M
1Y
5Y
1D
Helix Biopharma GAAP EPS of -$0.09
Seeking Alpha · 10/29/2025 21:49
Weekly Report: what happened at HBPCF last week (0908-0912)?
Weekly Report · 09/15/2025 11:06
Weekly Report: what happened at HBPCF last week (0901-0905)?
Weekly Report · 09/08/2025 11:08
Weekly Report: what happened at HBPCF last week (0825-0829)?
Weekly Report · 09/01/2025 11:03
Weekly Report: what happened at HBPCF last week (0818-0822)?
Weekly Report · 08/25/2025 11:14
Weekly Report: what happened at HBPCF last week (0811-0815)?
Weekly Report · 08/18/2025 11:06
Weekly Report: what happened at HBPCF last week (0804-0808)?
Weekly Report · 08/11/2025 11:13
Weekly Report: what happened at HBPCF last week (0728-0801)?
Weekly Report · 08/04/2025 11:15
More
About HBPCF
Helix BioPharma Corp. is a clinical-stage biopharmaceutical company developing therapies in the field of immuno-oncology for the prevention and treatment of cancer based on its proprietary technological platform DOS47. The Company’s pipeline is led by Tumor Defense Breaker L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and shares its CEACAM6-targeting foundation with the Company's next-generation bi-specific antibody-drug conjugates (ADCs), in discovery. The Company is also advancing two pre-IND candidates: LEUMUNA, an oral immune checkpoint modulator aimed at achieving durable remission in post-transplant leukemia relapse, and GEMCEDA, an oral gemcitabine prodrug with bioavailability on a par with IV, designed to expand treatment options for advanced cancers.

Webull offers Helix Biopharma Corp stock information, including OTCPK: HBPCF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HBPCF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HBPCF stock methods without spending real money on the virtual paper trading platform.